EGFR and non-small cell lung carcinoma: We further determined by IHC detection whether NNMT was associated with the therapeutic effect of EGFR-TKI in NSCLC patients with EGFR mutations (n = 50) who received EGFR-TKI (gefitinib or erlotinib) treatment.